Several studies, including a large meta-analysis encompassing almost 8000 ovarian cancer cases, have reported that BRCA1 and BRCA2 carriers have better survival than non-carriers [13,42,43,44,45,46], but the survival advantage diminishes with time from diagnosis. This evidence concerns the gene BRCA1 and ovarian cancer.